Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

diseases and oncology.

Third Quarter 2013 Highlights

  • Advanced Additional Therapeutic Programs; Proprietary Efforts Focused on Oncology and Orphan Diseases. Regulus continued to pursue several additional programs, both independently and with its strategic alliance partners, targeting miR-21 for oncology indications, targeting miR-221 for the treatment of HCC, targeting miR-10b for the treatment of glioblastoma, and targeting miR-33 for atherosclerosis. Additionally, Regulus continues to advance its proprietary efforts with the identification of several attractive microRNA targets, namely for oncology indications and orphan diseases.
  • Completed Successful Public Offering of Common Stock. Regulus completed an underwritten public offering of 5,175,000 shares of common stock resulting in $45.8 million of aggregate net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses payable by Regulus. Primarily as a result of the successful offering, Regulus revised its prior year-end cash guidance of ending 2013 with at least $60 million in cash, cash equivalents and short-term investments to ending 2013 with approximately $110 million in cash, cash equivalents and short-term investments.
  • Third Quarter 2013 Financial Results & HighlightsAs of September 30, 2013, Regulus had $123.9 million in cash, cash equivalents and short-term investments, including $45.8 million in net proceeds from a public offering of 5,175,000 shares of common stock issued at an offering price of $9.50 per share, which was completed in July 2013.  

    Regulus reported a net loss of $2.2 million for the three months ended September 30, 2013, compared to a net loss of $5.7 million for the same period in 2012.  Basic and diluted net loss per share was $0.05 and $0.07 for the three months ended September 30, 2013, respectively, compared to basic and di
    '/>"/>

    SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
    2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
    4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
    9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    11. Regulus to Present at Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
    (Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
    (Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
    Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
    ... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
    ... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
    Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
    (Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
    (Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
    (Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
    (Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
    (Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
    Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
    ... Calif., June 24 Novasys Medical, Inc., a developer ... as of July 1, 2009, First Coast Service Options, ... over 3 million beneficiaries in Florida, Puerto Rico and ... treatment for women with stress urinary incontinence (SUI) from ...
    ... Plans (MHP) is pleased to offer Mercy One ... www.mercyhealthplans.com . This online quoting and sales ... and brokers with Mercy One (TM), health insurance for ... Connect(TM) utilizes a customer-friendly online ecommerce platform that ...
    ... Purchase Agreement will expedite the purchasing process for groups ... IRVINE, Calif., June 24 ChromaDex Corp., (OTC Bulletin ... contract research, announced today that the National Institutes of ... Company. The Agreement covers all products and services ...
    ... , , , , Chocolate and ... June 24 Experimenting with flavors, flexibility and variety, ... with chocolate and candy innovation that will drive consumer purchasing ... Association,s (NCA) Confectionery Industry Trend Report 2009. Even in economic ...
    ... CNI ... Technician Executive Division of the California Society of Health System Pharmacists. , ... Orange, CA (PRWEB) June 24, 2009 -- CNI ... for the Technician Executive Division of the California Society of Health System Pharmacists. As ...
    ... Vet-A-Mix announces ... at-risk horses. , ... (PRWEB) June 24, 2009 -- Equine obesity is on the rise in the United States. ... higher risk for laminitis: a debilitating condition responsible for thousands of deaths each year. According ...
    Cached Medicine News:Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 2Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 3Health News:Mercy Health Plans Launches MercyOne Connect(TM) 2Health News:ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health 2Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 2Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 3Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 4Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 5Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 6Health News:CNI Pharmacy Technician Program 2Health News:Equine Obesity is Associated with Significant Health Issues, Including Insulin Resistance and Laminitis 2
    The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
    This unit is the finest standalone handswitch bipolar unit available....
    ...
    ...
    Medicine Products: